Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ALX Oncology Holdings ( (ALXO) ) just unveiled an update.
On January 30, 2026, ALX Oncology reported new data from a Phase 1b/2 trial of its CD47 inhibitor evorpacept in combination with Jazz Pharmaceuticals’ Ziihera (zanidatamab-hrii) in heavily pretreated patients with metastatic HER2-positive breast cancer, showing that higher CD47 expression was associated with response, reinforcing CD47 as a predictive biomarker as previously observed in HER2-positive gastric cancer. The company also disclosed preliminary, unaudited figures indicating it held approximately $48.3 million in cash, cash equivalents, and investments as of December 31, 2025, while stressing that these estimates are subject to change pending completion of its year-end close and audit, signaling both scientific momentum for its biomarker-driven development strategy and a constrained but defined financial runway for ongoing clinical programs.
The most recent analyst rating on (ALXO) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on ALX Oncology Holdings stock, see the ALXO Stock Forecast page.
Spark’s Take on ALXO Stock
According to Spark, TipRanks’ AI Analyst, ALXO is a Neutral.
The score is held back primarily by weak financial performance (pre-revenue, large losses and cash burn with a reduced balance-sheet cushion). Offsetting this are encouraging clinical/strategy updates and runway from the latest earnings call, plus improving technical momentum; valuation support is limited by a negative P/E and no dividend.
To see Spark’s full report on ALXO stock, click here.
More about ALX Oncology Holdings
ALX Oncology Holdings is a clinical-stage biotechnology company focused on developing novel cancer therapies, led by its investigational CD47 inhibitor evorpacept, which it aims to position as a cornerstone immuno-oncology agent across multiple tumor types. The company is also advancing ALX2004, a novel EGFR-targeted antibody-drug conjugate currently in a Phase 1 dose-escalation trial for patients with EGFR-expressing solid tumors.
Average Trading Volume: 254,863
Technical Sentiment Signal: Sell
Current Market Cap: $74.28M
Learn more about ALXO stock on TipRanks’ Stock Analysis page.